Biocon Q3: Analysts expect PAT growing 6% to Rs 90 cr
Healthcare firm Biocon is set to declare its third quarter results on Thursday. Analysts on an average expect profit after tax of the company to grow by 6 percent year-on-year to Rs 89.6 crore in the quarter.
January 24, 2013 / 18:13 IST
Healthcare firm Biocon is set to declare its third quarter results on Thursday. Analysts on an average expect profit after tax of the company to grow by 6 percent year-on-year to Rs 89.6 crore in the quarter.
Revenues are seen going up 19 percent to Rs 617 crore from Rs 519 crore during the same period, according to CNBC-TV18 poll. Earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to go up by 3 percent YoY to Rs 133 crore. The company, however, is likely disappoint the street on OPM front as analysts expect operating profit margin to fall 320 basis points YoY to 21.6 percent in October-December quarter.Analysts are expecting a nearly 20 percent growth in topline on the back of:->Biopharma segment that has been growing around 15-20 percent plus on an adjusted basis (ex-license fee from Pfizer). In previous quarter, it was subdued, growing only 8 percent YoY to Rs 372 crore; however on an adjusted basis, it was up 20 percent;->Expectations of 18-20 percent growth in CRAMS. In July-September quarter, it grew by 39 percent YoY to Rs 129 crore on the back of a tie up with Abbott Nutrition Research and incremental revenue from clients;->Branded formulation. This segment jumped 42 percent YoY to Rs 91 crore in second quarter of FY13, driven by diabetology + oncology divisions.Analysts expect licensing income to decline to around Rs 20 crore in the third quarter. In second quarter, Biocon did not book any license fee from Pfizer as against Rs 36 crore in year ago period.Analysts feel margins could decline due to higher R&D spend. In September quarter, margins were maintained at 24 percent despite higher R&D, mainly due to a onetime income booked during the quarter.Investors should watch out for commentary on Optimer, which was expected to launch Deficid (Fidaxomicin) in the EU market by the end of December 2012. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
